Global Emphysema Drug- Market

Emphysema Drug- Comprehensive Study by Drugs (Aclidinium Bromide Oral Inhalation, Albuterol and Ipratropium, Alpha One-proteinase inhibitor, Indacaterol, Others), Therapy (Pulmonary Rehabilitation, Nutrition Therapy, Supplemental Oxygen), Medications (Bronchodilators, Inhaled Steroids, Antibiotics), Surgery (Lung Volume Reduction Surgery, Lung Transplant), Diagnosis (Imaging Test, Lab Test, Spirometry, Others), Symptoms (Loss of appetite, Depression, Problems having sex, Sleep problems, Blue lips or nail beds, Fatigue, Frequent lung infections, Morning headaches, Weight loss, Others) Players and Region - Global Market Outlook to 2030

Emphysema Drug- Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Emphysema Drug-
Emphysema is a lung situation that motives shortness of breath. Emphysema is a disorder of the lungs that commonly develops after many years of smoking. Both continual bronchitis and emphysema belong to a crew of lung ailments recognised as persistent obstructive pulmonary ailment (COPD). Emphysema tends to have an effect on adults, in particular these who are over the age of forty Emphysema assaults lung tissue, which reasons a breakdown over time.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Emphysema Drug- market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline (GSK) (United Kingdom), Novartis AG (Switzerland), Merck & Co. (United States), Abbott Laboratories (United States), Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (United Kingdom) and Pfizer (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Mylan (United States), Aerovance Inc. (United States), Alkermes Inc. (Ireland) and Almirall SA. (Spain).

Segmentation Overview
AMA Research has segmented the market of Global Emphysema Drug- market by and Region.



On the basis of geography, the market of Emphysema Drug- has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drugs, the sub-segment i.e. Aclidinium Bromide Oral Inhalation will boost the Emphysema Drug- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapy, the sub-segment i.e. Pulmonary Rehabilitation will boost the Emphysema Drug- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Medications , the sub-segment i.e. Bronchodilators will boost the Emphysema Drug- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Surgery, the sub-segment i.e. Lung Volume Reduction Surgery will boost the Emphysema Drug- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Imaging Test will boost the Emphysema Drug- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Loss of appetite will boost the Emphysema Drug- market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
New Products that Comprises improved Capabilities Launched by Leading Players

Market Growth Drivers:
Increased Smoking, Increased Air Pollution, and Presence of Chronic Lungs Diseases

Challenges:
Stringent Government Regulatory Requirement for the Approval of Asthma Drugs

Restraints:
High Cost required for Approval of Drugs and Side Effects, Patent Expiry of the Drugs

Opportunities:
Technological Advancement in the Treatment and Introduction of Generic Drugs in Developing Countries

Market Leaders and their expansionary development strategies
In June 2022, Glenmark launched the novel-fixed dose combination (FDC) drug, Indacaterol plus Mometasone for patients suffering from uncontrollable asthma in India, The company launched this FDC under the brand name Indamet.
In 2021, Merck & Co, Inc successfully developed and launched Januvia, its drug for type 2 diabetes. Merck was in urgent need of a new blockbuster drug as it had been reeling under the numerous product liability lawsuits related to its pain relief drug Vioxx, the expiry of its blockbuster cholesterol drug, Zocor and the imminent expiry of three more blockbuster drugs.
In January 2021, Olympus announced the launch of FDA approved spiration valve system, which provides a minimally invasive treatment alternative for eligible patients.

Key Target Audience
Manufacturers, Distributors and Suppliers, Venture Capitalists and Private Equity Firms, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Drugs
  • Aclidinium Bromide Oral Inhalation
  • Albuterol and Ipratropium
  • Alpha One-proteinase inhibitor
  • Indacaterol
  • Others

By Therapy
  • Pulmonary Rehabilitation
  • Nutrition Therapy
  • Supplemental Oxygen

By Medications
  • Bronchodilators
  • Inhaled Steroids
  • Antibiotics

By Surgery
  • Lung Volume Reduction Surgery
  • Lung Transplant

By Diagnosis
  • Imaging Test
  • Lab Test
  • Spirometry
  • Others

By Symptoms
  • Loss of appetite
  • Depression
  • Problems having sex
  • Sleep problems
  • Blue lips or nail beds
  • Fatigue
  • Frequent lung infections
  • Morning headaches
  • Weight loss
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Smoking, Increased Air Pollution, and Presence of Chronic Lungs Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulatory Requirement for the Approval of Asthma Drugs
    • 3.4. Market Trends
      • 3.4.1. New Products that Comprises improved Capabilities Launched by Leading Players
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Emphysema Drug-, by Drugs, Therapy, Medications , Surgery, Diagnosis, Symptoms and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Emphysema Drug- (Value)
      • 5.2.1. Global Emphysema Drug- by: Drugs (Value)
        • 5.2.1.1. Aclidinium Bromide Oral Inhalation
        • 5.2.1.2. Albuterol and Ipratropium
        • 5.2.1.3. Alpha One-proteinase inhibitor
        • 5.2.1.4. Indacaterol
        • 5.2.1.5. Others
      • 5.2.2. Global Emphysema Drug- by: Therapy (Value)
        • 5.2.2.1. Pulmonary Rehabilitation
        • 5.2.2.2. Nutrition Therapy
        • 5.2.2.3. Supplemental Oxygen
      • 5.2.3. Global Emphysema Drug- by: Surgery (Value)
        • 5.2.3.1. Lung Volume Reduction Surgery
        • 5.2.3.2. Lung Transplant
      • 5.2.4. Global Emphysema Drug- by: Diagnosis (Value)
        • 5.2.4.1. Imaging Test
        • 5.2.4.2. Lab Test
        • 5.2.4.3. Spirometry
        • 5.2.4.4. Others
      • 5.2.5. Global Emphysema Drug- by: Symptoms (Value)
        • 5.2.5.1. Loss of appetite
        • 5.2.5.2. Depression
        • 5.2.5.3. Problems having sex
        • 5.2.5.4. Sleep problems
        • 5.2.5.5. Blue lips or nail beds
        • 5.2.5.6. Fatigue
        • 5.2.5.7. Frequent lung infections
        • 5.2.5.8. Morning headaches
        • 5.2.5.9. Weight loss
        • 5.2.5.10. Others
      • 5.2.6. Global Emphysema Drug- Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Australia
          • 5.2.6.2.6. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Emphysema Drug- (Volume)
      • 5.3.1. Global Emphysema Drug- by: Drugs (Volume)
        • 5.3.1.1. Aclidinium Bromide Oral Inhalation
        • 5.3.1.2. Albuterol and Ipratropium
        • 5.3.1.3. Alpha One-proteinase inhibitor
        • 5.3.1.4. Indacaterol
        • 5.3.1.5. Others
      • 5.3.2. Global Emphysema Drug- by: Therapy (Volume)
        • 5.3.2.1. Pulmonary Rehabilitation
        • 5.3.2.2. Nutrition Therapy
        • 5.3.2.3. Supplemental Oxygen
      • 5.3.3. Global Emphysema Drug- by: Surgery (Volume)
        • 5.3.3.1. Lung Volume Reduction Surgery
        • 5.3.3.2. Lung Transplant
      • 5.3.4. Global Emphysema Drug- by: Diagnosis (Volume)
        • 5.3.4.1. Imaging Test
        • 5.3.4.2. Lab Test
        • 5.3.4.3. Spirometry
        • 5.3.4.4. Others
      • 5.3.5. Global Emphysema Drug- by: Symptoms (Volume)
        • 5.3.5.1. Loss of appetite
        • 5.3.5.2. Depression
        • 5.3.5.3. Problems having sex
        • 5.3.5.4. Sleep problems
        • 5.3.5.5. Blue lips or nail beds
        • 5.3.5.6. Fatigue
        • 5.3.5.7. Frequent lung infections
        • 5.3.5.8. Morning headaches
        • 5.3.5.9. Weight loss
        • 5.3.5.10. Others
      • 5.3.6. Global Emphysema Drug- Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Australia
          • 5.3.6.2.6. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Emphysema Drug- (Price)
  • 6. Emphysema Drug-: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline (GSK) (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boehringer Ingelheim (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. AstraZeneca (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche Holding AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vectura Group (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Emphysema Drug- Sale, by Drugs, Therapy, Medications , Surgery, Diagnosis, Symptoms and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Emphysema Drug- (Value)
      • 7.2.1. Global Emphysema Drug- by: Drugs (Value)
        • 7.2.1.1. Aclidinium Bromide Oral Inhalation
        • 7.2.1.2. Albuterol and Ipratropium
        • 7.2.1.3. Alpha One-proteinase inhibitor
        • 7.2.1.4. Indacaterol
        • 7.2.1.5. Others
      • 7.2.2. Global Emphysema Drug- by: Therapy (Value)
        • 7.2.2.1. Pulmonary Rehabilitation
        • 7.2.2.2. Nutrition Therapy
        • 7.2.2.3. Supplemental Oxygen
      • 7.2.3. Global Emphysema Drug- by: Surgery (Value)
        • 7.2.3.1. Lung Volume Reduction Surgery
        • 7.2.3.2. Lung Transplant
      • 7.2.4. Global Emphysema Drug- by: Diagnosis (Value)
        • 7.2.4.1. Imaging Test
        • 7.2.4.2. Lab Test
        • 7.2.4.3. Spirometry
        • 7.2.4.4. Others
      • 7.2.5. Global Emphysema Drug- by: Symptoms (Value)
        • 7.2.5.1. Loss of appetite
        • 7.2.5.2. Depression
        • 7.2.5.3. Problems having sex
        • 7.2.5.4. Sleep problems
        • 7.2.5.5. Blue lips or nail beds
        • 7.2.5.6. Fatigue
        • 7.2.5.7. Frequent lung infections
        • 7.2.5.8. Morning headaches
        • 7.2.5.9. Weight loss
        • 7.2.5.10. Others
      • 7.2.6. Global Emphysema Drug- Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Australia
          • 7.2.6.2.6. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Emphysema Drug- (Volume)
      • 7.3.1. Global Emphysema Drug- by: Drugs (Volume)
        • 7.3.1.1. Aclidinium Bromide Oral Inhalation
        • 7.3.1.2. Albuterol and Ipratropium
        • 7.3.1.3. Alpha One-proteinase inhibitor
        • 7.3.1.4. Indacaterol
        • 7.3.1.5. Others
      • 7.3.2. Global Emphysema Drug- by: Therapy (Volume)
        • 7.3.2.1. Pulmonary Rehabilitation
        • 7.3.2.2. Nutrition Therapy
        • 7.3.2.3. Supplemental Oxygen
      • 7.3.3. Global Emphysema Drug- by: Surgery (Volume)
        • 7.3.3.1. Lung Volume Reduction Surgery
        • 7.3.3.2. Lung Transplant
      • 7.3.4. Global Emphysema Drug- by: Diagnosis (Volume)
        • 7.3.4.1. Imaging Test
        • 7.3.4.2. Lab Test
        • 7.3.4.3. Spirometry
        • 7.3.4.4. Others
      • 7.3.5. Global Emphysema Drug- by: Symptoms (Volume)
        • 7.3.5.1. Loss of appetite
        • 7.3.5.2. Depression
        • 7.3.5.3. Problems having sex
        • 7.3.5.4. Sleep problems
        • 7.3.5.5. Blue lips or nail beds
        • 7.3.5.6. Fatigue
        • 7.3.5.7. Frequent lung infections
        • 7.3.5.8. Morning headaches
        • 7.3.5.9. Weight loss
        • 7.3.5.10. Others
      • 7.3.6. Global Emphysema Drug- Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Australia
          • 7.3.6.2.6. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Emphysema Drug- (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Emphysema Drug-: by Drugs(USD Million)
  • Table 2. Emphysema Drug- Aclidinium Bromide Oral Inhalation , by Region USD Million (2018-2023)
  • Table 3. Emphysema Drug- Albuterol and Ipratropium , by Region USD Million (2018-2023)
  • Table 4. Emphysema Drug- Alpha One-proteinase inhibitor , by Region USD Million (2018-2023)
  • Table 5. Emphysema Drug- Indacaterol , by Region USD Million (2018-2023)
  • Table 6. Emphysema Drug- Others , by Region USD Million (2018-2023)
  • Table 7. Emphysema Drug-: by Therapy(USD Million)
  • Table 8. Emphysema Drug- Pulmonary Rehabilitation , by Region USD Million (2018-2023)
  • Table 9. Emphysema Drug- Nutrition Therapy , by Region USD Million (2018-2023)
  • Table 10. Emphysema Drug- Supplemental Oxygen , by Region USD Million (2018-2023)
  • Table 11. Emphysema Drug-: by Surgery(USD Million)
  • Table 12. Emphysema Drug- Lung Volume Reduction Surgery , by Region USD Million (2018-2023)
  • Table 13. Emphysema Drug- Lung Transplant , by Region USD Million (2018-2023)
  • Table 14. Emphysema Drug-: by Diagnosis(USD Million)
  • Table 15. Emphysema Drug- Imaging Test , by Region USD Million (2018-2023)
  • Table 16. Emphysema Drug- Lab Test , by Region USD Million (2018-2023)
  • Table 17. Emphysema Drug- Spirometry , by Region USD Million (2018-2023)
  • Table 18. Emphysema Drug- Others , by Region USD Million (2018-2023)
  • Table 19. Emphysema Drug-: by Symptoms(USD Million)
  • Table 20. Emphysema Drug- Loss of appetite , by Region USD Million (2018-2023)
  • Table 21. Emphysema Drug- Depression , by Region USD Million (2018-2023)
  • Table 22. Emphysema Drug- Problems having sex , by Region USD Million (2018-2023)
  • Table 23. Emphysema Drug- Sleep problems , by Region USD Million (2018-2023)
  • Table 24. Emphysema Drug- Blue lips or nail beds , by Region USD Million (2018-2023)
  • Table 25. Emphysema Drug- Fatigue , by Region USD Million (2018-2023)
  • Table 26. Emphysema Drug- Frequent lung infections , by Region USD Million (2018-2023)
  • Table 27. Emphysema Drug- Morning headaches , by Region USD Million (2018-2023)
  • Table 28. Emphysema Drug- Weight loss , by Region USD Million (2018-2023)
  • Table 29. Emphysema Drug- Others , by Region USD Million (2018-2023)
  • Table 30. South America Emphysema Drug-, by Country USD Million (2018-2023)
  • Table 31. South America Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 32. South America Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 33. South America Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 34. South America Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 35. South America Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 36. South America Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 37. Brazil Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 38. Brazil Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 39. Brazil Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 40. Brazil Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 41. Brazil Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 42. Brazil Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 43. Argentina Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 44. Argentina Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 45. Argentina Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 46. Argentina Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 47. Argentina Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 48. Argentina Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 49. Rest of South America Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 50. Rest of South America Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 51. Rest of South America Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 52. Rest of South America Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 53. Rest of South America Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 54. Rest of South America Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 55. Asia Pacific Emphysema Drug-, by Country USD Million (2018-2023)
  • Table 56. Asia Pacific Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 57. Asia Pacific Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 58. Asia Pacific Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 59. Asia Pacific Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 60. Asia Pacific Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 61. Asia Pacific Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 62. China Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 63. China Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 64. China Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 65. China Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 66. China Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 67. China Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 68. Japan Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 69. Japan Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 70. Japan Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 71. Japan Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 72. Japan Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 73. Japan Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 74. India Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 75. India Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 76. India Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 77. India Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 78. India Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 79. India Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 80. South Korea Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 81. South Korea Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 82. South Korea Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 83. South Korea Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 84. South Korea Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 85. South Korea Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 86. Australia Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 87. Australia Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 88. Australia Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 89. Australia Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 90. Australia Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 91. Australia Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 92. Rest of Asia-Pacific Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 93. Rest of Asia-Pacific Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 94. Rest of Asia-Pacific Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 95. Rest of Asia-Pacific Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 96. Rest of Asia-Pacific Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 97. Rest of Asia-Pacific Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 98. Europe Emphysema Drug-, by Country USD Million (2018-2023)
  • Table 99. Europe Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 100. Europe Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 101. Europe Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 102. Europe Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 103. Europe Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 104. Europe Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 105. Germany Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 106. Germany Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 107. Germany Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 108. Germany Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 109. Germany Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 110. Germany Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 111. France Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 112. France Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 113. France Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 114. France Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 115. France Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 116. France Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 117. Italy Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 118. Italy Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 119. Italy Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 120. Italy Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 121. Italy Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 122. Italy Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 123. United Kingdom Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 124. United Kingdom Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 125. United Kingdom Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 126. United Kingdom Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 127. United Kingdom Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 128. United Kingdom Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 129. Netherlands Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 130. Netherlands Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 131. Netherlands Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 132. Netherlands Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 133. Netherlands Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 134. Netherlands Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 135. Rest of Europe Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 136. Rest of Europe Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 137. Rest of Europe Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 138. Rest of Europe Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 139. Rest of Europe Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 140. Rest of Europe Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 141. MEA Emphysema Drug-, by Country USD Million (2018-2023)
  • Table 142. MEA Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 143. MEA Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 144. MEA Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 145. MEA Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 146. MEA Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 147. MEA Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 148. Middle East Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 149. Middle East Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 150. Middle East Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 151. Middle East Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 152. Middle East Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 153. Middle East Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 154. Africa Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 155. Africa Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 156. Africa Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 157. Africa Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 158. Africa Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 159. Africa Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 160. North America Emphysema Drug-, by Country USD Million (2018-2023)
  • Table 161. North America Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 162. North America Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 163. North America Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 164. North America Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 165. North America Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 166. North America Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 167. United States Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 168. United States Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 169. United States Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 170. United States Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 171. United States Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 172. United States Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 173. Canada Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 174. Canada Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 175. Canada Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 176. Canada Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 177. Canada Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 178. Canada Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 179. Mexico Emphysema Drug-, by Drugs USD Million (2018-2023)
  • Table 180. Mexico Emphysema Drug-, by Therapy USD Million (2018-2023)
  • Table 181. Mexico Emphysema Drug-, by Medications USD Million (2018-2023)
  • Table 182. Mexico Emphysema Drug-, by Surgery USD Million (2018-2023)
  • Table 183. Mexico Emphysema Drug-, by Diagnosis USD Million (2018-2023)
  • Table 184. Mexico Emphysema Drug-, by Symptoms USD Million (2018-2023)
  • Table 185. Emphysema Drug- Sales: by Drugs(K Units)
  • Table 186. Emphysema Drug- Sales Aclidinium Bromide Oral Inhalation , by Region K Units (2018-2023)
  • Table 187. Emphysema Drug- Sales Albuterol and Ipratropium , by Region K Units (2018-2023)
  • Table 188. Emphysema Drug- Sales Alpha One-proteinase inhibitor , by Region K Units (2018-2023)
  • Table 189. Emphysema Drug- Sales Indacaterol , by Region K Units (2018-2023)
  • Table 190. Emphysema Drug- Sales Others , by Region K Units (2018-2023)
  • Table 191. Emphysema Drug- Sales: by Therapy(K Units)
  • Table 192. Emphysema Drug- Sales Pulmonary Rehabilitation , by Region K Units (2018-2023)
  • Table 193. Emphysema Drug- Sales Nutrition Therapy , by Region K Units (2018-2023)
  • Table 194. Emphysema Drug- Sales Supplemental Oxygen , by Region K Units (2018-2023)
  • Table 195. Emphysema Drug- Sales: by Surgery(K Units)
  • Table 196. Emphysema Drug- Sales Lung Volume Reduction Surgery , by Region K Units (2018-2023)
  • Table 197. Emphysema Drug- Sales Lung Transplant , by Region K Units (2018-2023)
  • Table 198. Emphysema Drug- Sales: by Diagnosis(K Units)
  • Table 199. Emphysema Drug- Sales Imaging Test , by Region K Units (2018-2023)
  • Table 200. Emphysema Drug- Sales Lab Test , by Region K Units (2018-2023)
  • Table 201. Emphysema Drug- Sales Spirometry , by Region K Units (2018-2023)
  • Table 202. Emphysema Drug- Sales Others , by Region K Units (2018-2023)
  • Table 203. Emphysema Drug- Sales: by Symptoms(K Units)
  • Table 204. Emphysema Drug- Sales Loss of appetite , by Region K Units (2018-2023)
  • Table 205. Emphysema Drug- Sales Depression , by Region K Units (2018-2023)
  • Table 206. Emphysema Drug- Sales Problems having sex , by Region K Units (2018-2023)
  • Table 207. Emphysema Drug- Sales Sleep problems , by Region K Units (2018-2023)
  • Table 208. Emphysema Drug- Sales Blue lips or nail beds , by Region K Units (2018-2023)
  • Table 209. Emphysema Drug- Sales Fatigue , by Region K Units (2018-2023)
  • Table 210. Emphysema Drug- Sales Frequent lung infections , by Region K Units (2018-2023)
  • Table 211. Emphysema Drug- Sales Morning headaches , by Region K Units (2018-2023)
  • Table 212. Emphysema Drug- Sales Weight loss , by Region K Units (2018-2023)
  • Table 213. Emphysema Drug- Sales Others , by Region K Units (2018-2023)
  • Table 214. South America Emphysema Drug- Sales, by Country K Units (2018-2023)
  • Table 215. South America Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 216. South America Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 217. South America Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 218. South America Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 219. South America Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 220. South America Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 221. Brazil Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 222. Brazil Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 223. Brazil Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 224. Brazil Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 225. Brazil Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 226. Brazil Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 227. Argentina Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 228. Argentina Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 229. Argentina Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 230. Argentina Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 231. Argentina Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 232. Argentina Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 233. Rest of South America Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 234. Rest of South America Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 235. Rest of South America Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 236. Rest of South America Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 237. Rest of South America Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 238. Rest of South America Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 239. Asia Pacific Emphysema Drug- Sales, by Country K Units (2018-2023)
  • Table 240. Asia Pacific Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 241. Asia Pacific Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 242. Asia Pacific Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 243. Asia Pacific Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 244. Asia Pacific Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 245. Asia Pacific Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 246. China Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 247. China Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 248. China Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 249. China Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 250. China Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 251. China Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 252. Japan Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 253. Japan Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 254. Japan Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 255. Japan Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 256. Japan Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 257. Japan Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 258. India Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 259. India Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 260. India Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 261. India Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 262. India Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 263. India Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 264. South Korea Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 265. South Korea Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 266. South Korea Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 267. South Korea Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 268. South Korea Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 269. South Korea Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 270. Australia Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 271. Australia Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 272. Australia Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 273. Australia Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 274. Australia Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 275. Australia Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 276. Rest of Asia-Pacific Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 277. Rest of Asia-Pacific Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 278. Rest of Asia-Pacific Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 279. Rest of Asia-Pacific Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 280. Rest of Asia-Pacific Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 281. Rest of Asia-Pacific Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 282. Europe Emphysema Drug- Sales, by Country K Units (2018-2023)
  • Table 283. Europe Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 284. Europe Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 285. Europe Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 286. Europe Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 287. Europe Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 288. Europe Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 289. Germany Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 290. Germany Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 291. Germany Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 292. Germany Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 293. Germany Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 294. Germany Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 295. France Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 296. France Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 297. France Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 298. France Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 299. France Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 300. France Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 301. Italy Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 302. Italy Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 303. Italy Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 304. Italy Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 305. Italy Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 306. Italy Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 307. United Kingdom Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 308. United Kingdom Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 309. United Kingdom Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 310. United Kingdom Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 311. United Kingdom Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 312. United Kingdom Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 313. Netherlands Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 314. Netherlands Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 315. Netherlands Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 316. Netherlands Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 317. Netherlands Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 318. Netherlands Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 319. Rest of Europe Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 320. Rest of Europe Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 321. Rest of Europe Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 322. Rest of Europe Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 323. Rest of Europe Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 324. Rest of Europe Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 325. MEA Emphysema Drug- Sales, by Country K Units (2018-2023)
  • Table 326. MEA Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 327. MEA Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 328. MEA Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 329. MEA Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 330. MEA Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 331. MEA Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 332. Middle East Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 333. Middle East Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 334. Middle East Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 335. Middle East Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 336. Middle East Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 337. Middle East Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 338. Africa Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 339. Africa Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 340. Africa Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 341. Africa Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 342. Africa Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 343. Africa Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 344. North America Emphysema Drug- Sales, by Country K Units (2018-2023)
  • Table 345. North America Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 346. North America Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 347. North America Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 348. North America Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 349. North America Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 350. North America Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 351. United States Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 352. United States Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 353. United States Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 354. United States Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 355. United States Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 356. United States Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 357. Canada Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 358. Canada Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 359. Canada Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 360. Canada Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 361. Canada Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 362. Canada Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 363. Mexico Emphysema Drug- Sales, by Drugs K Units (2018-2023)
  • Table 364. Mexico Emphysema Drug- Sales, by Therapy K Units (2018-2023)
  • Table 365. Mexico Emphysema Drug- Sales, by Medications K Units (2018-2023)
  • Table 366. Mexico Emphysema Drug- Sales, by Surgery K Units (2018-2023)
  • Table 367. Mexico Emphysema Drug- Sales, by Diagnosis K Units (2018-2023)
  • Table 368. Mexico Emphysema Drug- Sales, by Symptoms K Units (2018-2023)
  • Table 369. Company Basic Information, Sales Area and Its Competitors
  • Table 370. Company Basic Information, Sales Area and Its Competitors
  • Table 371. Company Basic Information, Sales Area and Its Competitors
  • Table 372. Company Basic Information, Sales Area and Its Competitors
  • Table 373. Company Basic Information, Sales Area and Its Competitors
  • Table 374. Company Basic Information, Sales Area and Its Competitors
  • Table 375. Company Basic Information, Sales Area and Its Competitors
  • Table 376. Company Basic Information, Sales Area and Its Competitors
  • Table 377. Company Basic Information, Sales Area and Its Competitors
  • Table 378. Company Basic Information, Sales Area and Its Competitors
  • Table 379. Emphysema Drug-: by Drugs(USD Million)
  • Table 380. Emphysema Drug- Aclidinium Bromide Oral Inhalation , by Region USD Million (2025-2030)
  • Table 381. Emphysema Drug- Albuterol and Ipratropium , by Region USD Million (2025-2030)
  • Table 382. Emphysema Drug- Alpha One-proteinase inhibitor , by Region USD Million (2025-2030)
  • Table 383. Emphysema Drug- Indacaterol , by Region USD Million (2025-2030)
  • Table 384. Emphysema Drug- Others , by Region USD Million (2025-2030)
  • Table 385. Emphysema Drug-: by Therapy(USD Million)
  • Table 386. Emphysema Drug- Pulmonary Rehabilitation , by Region USD Million (2025-2030)
  • Table 387. Emphysema Drug- Nutrition Therapy , by Region USD Million (2025-2030)
  • Table 388. Emphysema Drug- Supplemental Oxygen , by Region USD Million (2025-2030)
  • Table 389. Emphysema Drug-: by Surgery(USD Million)
  • Table 390. Emphysema Drug- Lung Volume Reduction Surgery , by Region USD Million (2025-2030)
  • Table 391. Emphysema Drug- Lung Transplant , by Region USD Million (2025-2030)
  • Table 392. Emphysema Drug-: by Diagnosis(USD Million)
  • Table 393. Emphysema Drug- Imaging Test , by Region USD Million (2025-2030)
  • Table 394. Emphysema Drug- Lab Test , by Region USD Million (2025-2030)
  • Table 395. Emphysema Drug- Spirometry , by Region USD Million (2025-2030)
  • Table 396. Emphysema Drug- Others , by Region USD Million (2025-2030)
  • Table 397. Emphysema Drug-: by Symptoms(USD Million)
  • Table 398. Emphysema Drug- Loss of appetite , by Region USD Million (2025-2030)
  • Table 399. Emphysema Drug- Depression , by Region USD Million (2025-2030)
  • Table 400. Emphysema Drug- Problems having sex , by Region USD Million (2025-2030)
  • Table 401. Emphysema Drug- Sleep problems , by Region USD Million (2025-2030)
  • Table 402. Emphysema Drug- Blue lips or nail beds , by Region USD Million (2025-2030)
  • Table 403. Emphysema Drug- Fatigue , by Region USD Million (2025-2030)
  • Table 404. Emphysema Drug- Frequent lung infections , by Region USD Million (2025-2030)
  • Table 405. Emphysema Drug- Morning headaches , by Region USD Million (2025-2030)
  • Table 406. Emphysema Drug- Weight loss , by Region USD Million (2025-2030)
  • Table 407. Emphysema Drug- Others , by Region USD Million (2025-2030)
  • Table 408. South America Emphysema Drug-, by Country USD Million (2025-2030)
  • Table 409. South America Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 410. South America Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 411. South America Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 412. South America Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 413. South America Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 414. South America Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 415. Brazil Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 416. Brazil Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 417. Brazil Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 418. Brazil Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 419. Brazil Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 420. Brazil Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 421. Argentina Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 422. Argentina Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 423. Argentina Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 424. Argentina Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 425. Argentina Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 426. Argentina Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 427. Rest of South America Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 428. Rest of South America Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 429. Rest of South America Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 430. Rest of South America Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 431. Rest of South America Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 432. Rest of South America Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 433. Asia Pacific Emphysema Drug-, by Country USD Million (2025-2030)
  • Table 434. Asia Pacific Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 435. Asia Pacific Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 436. Asia Pacific Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 437. Asia Pacific Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 438. Asia Pacific Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 439. Asia Pacific Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 440. China Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 441. China Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 442. China Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 443. China Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 444. China Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 445. China Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 446. Japan Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 447. Japan Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 448. Japan Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 449. Japan Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 450. Japan Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 451. Japan Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 452. India Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 453. India Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 454. India Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 455. India Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 456. India Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 457. India Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 458. South Korea Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 459. South Korea Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 460. South Korea Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 461. South Korea Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 462. South Korea Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 463. South Korea Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 464. Australia Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 465. Australia Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 466. Australia Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 467. Australia Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 468. Australia Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 469. Australia Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 470. Rest of Asia-Pacific Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 471. Rest of Asia-Pacific Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 472. Rest of Asia-Pacific Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 473. Rest of Asia-Pacific Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 474. Rest of Asia-Pacific Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 475. Rest of Asia-Pacific Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 476. Europe Emphysema Drug-, by Country USD Million (2025-2030)
  • Table 477. Europe Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 478. Europe Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 479. Europe Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 480. Europe Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 481. Europe Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 482. Europe Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 483. Germany Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 484. Germany Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 485. Germany Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 486. Germany Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 487. Germany Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 488. Germany Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 489. France Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 490. France Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 491. France Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 492. France Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 493. France Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 494. France Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 495. Italy Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 496. Italy Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 497. Italy Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 498. Italy Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 499. Italy Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 500. Italy Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 501. United Kingdom Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 502. United Kingdom Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 503. United Kingdom Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 504. United Kingdom Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 505. United Kingdom Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 506. United Kingdom Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 507. Netherlands Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 508. Netherlands Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 509. Netherlands Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 510. Netherlands Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 511. Netherlands Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 512. Netherlands Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 513. Rest of Europe Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 514. Rest of Europe Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 515. Rest of Europe Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 516. Rest of Europe Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 517. Rest of Europe Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 518. Rest of Europe Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 519. MEA Emphysema Drug-, by Country USD Million (2025-2030)
  • Table 520. MEA Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 521. MEA Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 522. MEA Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 523. MEA Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 524. MEA Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 525. MEA Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 526. Middle East Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 527. Middle East Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 528. Middle East Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 529. Middle East Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 530. Middle East Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 531. Middle East Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 532. Africa Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 533. Africa Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 534. Africa Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 535. Africa Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 536. Africa Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 537. Africa Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 538. North America Emphysema Drug-, by Country USD Million (2025-2030)
  • Table 539. North America Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 540. North America Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 541. North America Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 542. North America Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 543. North America Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 544. North America Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 545. United States Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 546. United States Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 547. United States Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 548. United States Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 549. United States Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 550. United States Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 551. Canada Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 552. Canada Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 553. Canada Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 554. Canada Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 555. Canada Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 556. Canada Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 557. Mexico Emphysema Drug-, by Drugs USD Million (2025-2030)
  • Table 558. Mexico Emphysema Drug-, by Therapy USD Million (2025-2030)
  • Table 559. Mexico Emphysema Drug-, by Medications USD Million (2025-2030)
  • Table 560. Mexico Emphysema Drug-, by Surgery USD Million (2025-2030)
  • Table 561. Mexico Emphysema Drug-, by Diagnosis USD Million (2025-2030)
  • Table 562. Mexico Emphysema Drug-, by Symptoms USD Million (2025-2030)
  • Table 563. Emphysema Drug- Sales: by Drugs(K Units)
  • Table 564. Emphysema Drug- Sales Aclidinium Bromide Oral Inhalation , by Region K Units (2025-2030)
  • Table 565. Emphysema Drug- Sales Albuterol and Ipratropium , by Region K Units (2025-2030)
  • Table 566. Emphysema Drug- Sales Alpha One-proteinase inhibitor , by Region K Units (2025-2030)
  • Table 567. Emphysema Drug- Sales Indacaterol , by Region K Units (2025-2030)
  • Table 568. Emphysema Drug- Sales Others , by Region K Units (2025-2030)
  • Table 569. Emphysema Drug- Sales: by Therapy(K Units)
  • Table 570. Emphysema Drug- Sales Pulmonary Rehabilitation , by Region K Units (2025-2030)
  • Table 571. Emphysema Drug- Sales Nutrition Therapy , by Region K Units (2025-2030)
  • Table 572. Emphysema Drug- Sales Supplemental Oxygen , by Region K Units (2025-2030)
  • Table 573. Emphysema Drug- Sales: by Surgery(K Units)
  • Table 574. Emphysema Drug- Sales Lung Volume Reduction Surgery , by Region K Units (2025-2030)
  • Table 575. Emphysema Drug- Sales Lung Transplant , by Region K Units (2025-2030)
  • Table 576. Emphysema Drug- Sales: by Diagnosis(K Units)
  • Table 577. Emphysema Drug- Sales Imaging Test , by Region K Units (2025-2030)
  • Table 578. Emphysema Drug- Sales Lab Test , by Region K Units (2025-2030)
  • Table 579. Emphysema Drug- Sales Spirometry , by Region K Units (2025-2030)
  • Table 580. Emphysema Drug- Sales Others , by Region K Units (2025-2030)
  • Table 581. Emphysema Drug- Sales: by Symptoms(K Units)
  • Table 582. Emphysema Drug- Sales Loss of appetite , by Region K Units (2025-2030)
  • Table 583. Emphysema Drug- Sales Depression , by Region K Units (2025-2030)
  • Table 584. Emphysema Drug- Sales Problems having sex , by Region K Units (2025-2030)
  • Table 585. Emphysema Drug- Sales Sleep problems , by Region K Units (2025-2030)
  • Table 586. Emphysema Drug- Sales Blue lips or nail beds , by Region K Units (2025-2030)
  • Table 587. Emphysema Drug- Sales Fatigue , by Region K Units (2025-2030)
  • Table 588. Emphysema Drug- Sales Frequent lung infections , by Region K Units (2025-2030)
  • Table 589. Emphysema Drug- Sales Morning headaches , by Region K Units (2025-2030)
  • Table 590. Emphysema Drug- Sales Weight loss , by Region K Units (2025-2030)
  • Table 591. Emphysema Drug- Sales Others , by Region K Units (2025-2030)
  • Table 592. South America Emphysema Drug- Sales, by Country K Units (2025-2030)
  • Table 593. South America Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 594. South America Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 595. South America Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 596. South America Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 597. South America Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 598. South America Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 599. Brazil Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 600. Brazil Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 601. Brazil Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 602. Brazil Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 603. Brazil Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 604. Brazil Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 605. Argentina Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 606. Argentina Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 607. Argentina Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 608. Argentina Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 609. Argentina Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 610. Argentina Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 611. Rest of South America Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 612. Rest of South America Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 613. Rest of South America Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 614. Rest of South America Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 615. Rest of South America Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 616. Rest of South America Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 617. Asia Pacific Emphysema Drug- Sales, by Country K Units (2025-2030)
  • Table 618. Asia Pacific Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 619. Asia Pacific Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 620. Asia Pacific Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 621. Asia Pacific Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 622. Asia Pacific Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 623. Asia Pacific Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 624. China Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 625. China Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 626. China Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 627. China Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 628. China Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 629. China Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 630. Japan Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 631. Japan Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 632. Japan Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 633. Japan Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 634. Japan Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 635. Japan Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 636. India Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 637. India Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 638. India Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 639. India Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 640. India Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 641. India Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 642. South Korea Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 643. South Korea Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 644. South Korea Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 645. South Korea Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 646. South Korea Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 647. South Korea Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 648. Australia Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 649. Australia Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 650. Australia Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 651. Australia Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 652. Australia Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 653. Australia Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 654. Rest of Asia-Pacific Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 655. Rest of Asia-Pacific Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 656. Rest of Asia-Pacific Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 657. Rest of Asia-Pacific Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 658. Rest of Asia-Pacific Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 659. Rest of Asia-Pacific Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 660. Europe Emphysema Drug- Sales, by Country K Units (2025-2030)
  • Table 661. Europe Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 662. Europe Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 663. Europe Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 664. Europe Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 665. Europe Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 666. Europe Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 667. Germany Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 668. Germany Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 669. Germany Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 670. Germany Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 671. Germany Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 672. Germany Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 673. France Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 674. France Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 675. France Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 676. France Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 677. France Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 678. France Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 679. Italy Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 680. Italy Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 681. Italy Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 682. Italy Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 683. Italy Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 684. Italy Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 685. United Kingdom Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 686. United Kingdom Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 687. United Kingdom Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 688. United Kingdom Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 689. United Kingdom Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 690. United Kingdom Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 691. Netherlands Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 692. Netherlands Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 693. Netherlands Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 694. Netherlands Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 695. Netherlands Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 696. Netherlands Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 697. Rest of Europe Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 698. Rest of Europe Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 699. Rest of Europe Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 700. Rest of Europe Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 701. Rest of Europe Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 702. Rest of Europe Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 703. MEA Emphysema Drug- Sales, by Country K Units (2025-2030)
  • Table 704. MEA Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 705. MEA Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 706. MEA Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 707. MEA Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 708. MEA Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 709. MEA Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 710. Middle East Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 711. Middle East Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 712. Middle East Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 713. Middle East Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 714. Middle East Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 715. Middle East Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 716. Africa Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 717. Africa Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 718. Africa Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 719. Africa Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 720. Africa Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 721. Africa Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 722. North America Emphysema Drug- Sales, by Country K Units (2025-2030)
  • Table 723. North America Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 724. North America Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 725. North America Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 726. North America Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 727. North America Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 728. North America Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 729. United States Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 730. United States Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 731. United States Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 732. United States Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 733. United States Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 734. United States Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 735. Canada Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 736. Canada Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 737. Canada Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 738. Canada Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 739. Canada Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 740. Canada Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 741. Mexico Emphysema Drug- Sales, by Drugs K Units (2025-2030)
  • Table 742. Mexico Emphysema Drug- Sales, by Therapy K Units (2025-2030)
  • Table 743. Mexico Emphysema Drug- Sales, by Medications K Units (2025-2030)
  • Table 744. Mexico Emphysema Drug- Sales, by Surgery K Units (2025-2030)
  • Table 745. Mexico Emphysema Drug- Sales, by Diagnosis K Units (2025-2030)
  • Table 746. Mexico Emphysema Drug- Sales, by Symptoms K Units (2025-2030)
  • Table 747. Research Programs/Design for This Report
  • Table 748. Key Data Information from Secondary Sources
  • Table 749. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Emphysema Drug-: by Drugs USD Million (2018-2023)
  • Figure 5. Global Emphysema Drug-: by Therapy USD Million (2018-2023)
  • Figure 6. Global Emphysema Drug-: by Surgery USD Million (2018-2023)
  • Figure 7. Global Emphysema Drug-: by Diagnosis USD Million (2018-2023)
  • Figure 8. Global Emphysema Drug-: by Symptoms USD Million (2018-2023)
  • Figure 9. South America Emphysema Drug- Share (%), by Country
  • Figure 10. Asia Pacific Emphysema Drug- Share (%), by Country
  • Figure 11. Europe Emphysema Drug- Share (%), by Country
  • Figure 12. MEA Emphysema Drug- Share (%), by Country
  • Figure 13. North America Emphysema Drug- Share (%), by Country
  • Figure 14. Global Emphysema Drug-: by Drugs K Units (2018-2023)
  • Figure 15. Global Emphysema Drug-: by Therapy K Units (2018-2023)
  • Figure 16. Global Emphysema Drug-: by Surgery K Units (2018-2023)
  • Figure 17. Global Emphysema Drug-: by Diagnosis K Units (2018-2023)
  • Figure 18. Global Emphysema Drug-: by Symptoms K Units (2018-2023)
  • Figure 19. South America Emphysema Drug- Share (%), by Country
  • Figure 20. Asia Pacific Emphysema Drug- Share (%), by Country
  • Figure 21. Europe Emphysema Drug- Share (%), by Country
  • Figure 22. MEA Emphysema Drug- Share (%), by Country
  • Figure 23. North America Emphysema Drug- Share (%), by Country
  • Figure 24. Global Emphysema Drug- share by Players 2023 (%)
  • Figure 25. Global Emphysema Drug- share by Players (Top 3) 2023(%)
  • Figure 26. Global Emphysema Drug- share by Players (Top 5) 2023(%)
  • Figure 27. BCG Matrix for key Companies
  • Figure 28. GlaxoSmithKline (GSK) (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline (GSK) (United Kingdom) Revenue: by Geography 2023
  • Figure 30. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 32. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 34. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 35. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 36. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Boehringer Ingelheim (Germany) Revenue: by Geography 2023
  • Figure 38. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 40. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 41. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 42. Teva Pharmaceutical Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 43. Teva Pharmaceutical Industries (Israel) Revenue: by Geography 2023
  • Figure 44. Vectura Group (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 45. Vectura Group (United Kingdom) Revenue: by Geography 2023
  • Figure 46. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 47. Pfizer (United States) Revenue: by Geography 2023
  • Figure 48. Global Emphysema Drug-: by Drugs USD Million (2025-2030)
  • Figure 49. Global Emphysema Drug-: by Therapy USD Million (2025-2030)
  • Figure 50. Global Emphysema Drug-: by Surgery USD Million (2025-2030)
  • Figure 51. Global Emphysema Drug-: by Diagnosis USD Million (2025-2030)
  • Figure 52. Global Emphysema Drug-: by Symptoms USD Million (2025-2030)
  • Figure 53. South America Emphysema Drug- Share (%), by Country
  • Figure 54. Asia Pacific Emphysema Drug- Share (%), by Country
  • Figure 55. Europe Emphysema Drug- Share (%), by Country
  • Figure 56. MEA Emphysema Drug- Share (%), by Country
  • Figure 57. North America Emphysema Drug- Share (%), by Country
  • Figure 58. Global Emphysema Drug-: by Drugs K Units (2025-2030)
  • Figure 59. Global Emphysema Drug-: by Therapy K Units (2025-2030)
  • Figure 60. Global Emphysema Drug-: by Surgery K Units (2025-2030)
  • Figure 61. Global Emphysema Drug-: by Diagnosis K Units (2025-2030)
  • Figure 62. Global Emphysema Drug-: by Symptoms K Units (2025-2030)
  • Figure 63. South America Emphysema Drug- Share (%), by Country
  • Figure 64. Asia Pacific Emphysema Drug- Share (%), by Country
  • Figure 65. Europe Emphysema Drug- Share (%), by Country
  • Figure 66. MEA Emphysema Drug- Share (%), by Country
  • Figure 67. North America Emphysema Drug- Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline (GSK) (United Kingdom)
  • Novartis AG (Switzerland)
  • Merck & Co. (United States)
  • Abbott Laboratories (United States)
  • Boehringer Ingelheim (Germany)
  • AstraZeneca (United Kingdom)
  • Roche Holding AG (Switzerland)
  • Teva Pharmaceutical Industries (Israel)
  • Vectura Group (United Kingdom)
  • Pfizer (United States)
Additional players considered in the study are as follows:
Mylan (United States) , Aerovance Inc. (United States) , Alkermes Inc. (Ireland) , Almirall SA. (Spain)
Select User Access Type

Key Highlights of Report


Jan 2024 242 Pages 62 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Emphysema Drug- Market Quantitative research analysis
Global Emphysema Drug- Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline (GSK) (United Kingdom), Novartis AG (Switzerland), Merck & Co. (United States), Abbott Laboratories (United States), Boehringer Ingelheim (Germany), AstraZeneca (United Kingdom), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries (Israel), Vectura Group (United Kingdom) and Pfizer (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"New Products that Comprises improved Capabilities Launched by Leading Players" is seen as one of major influencing trends for Emphysema Drug- Market during projected period 2023-2030.
The Emphysema Drug- market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Emphysema Drug- Market Report?

Have a Query? Click Here

Other Related Reports

Tenosynovitis Drugs Comprehensive Study by Product type (Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Antibiotics, Corticosteroids), End user (Hospitals, Drugstores, Others) Players and Region - Gl...
$ 3500
Malnutrition_ Comprehensive Study by Type (Under Nutrition, Over Nutrition), Treatment (Intravenously (Par-enteral Nutrition), Gastrointestinal Tract (Enteral Nutrition)), Causes (A Low Intake Of Foo...
$ 3800
Immune Cell Therapy Comprehensive Study by Application (Cancer, Autoimmune Disease, Chronic Inflammation), Forms (Nonspecific Immunotherapies, Cancer Vaccines), End User (Hospitals, Cancer Research C...
$ 3400
Oxycodone Drug Comprehensive Study by Distribution Channel (Online {Company Website, E-Commerce Website}, Offline {Pharma Stores, Local Medical Stores}), End Use (Hospitals, Clinics, Diagnostic Cente...
$ 3800
Spiramycin Drug Comprehensive Study by Type (Oral route {Capsule, Tablets}, Rectal route {Suppository}, Injection route), Disease (Toxoplasmosis, Cryptosporidiosis), Distribution Channel (Hospital ph...
$ 3800
Argininemia Drugs- Comprehensive Study by Medications (Protein Intake Limited, Sodium Benzoate, Sodium Phenylbutyrate, Carglumic Acid, Others), Diagnosis (Plasma Ammonia Concentration, Urinary Orotic...
$ 3500